Clinical Firsts — Christiaan Barnard’s Heart Transplantations

McKellar, Shelley

doi:10.1056/nejmp1707919

Cited by 9 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since human heart transplantation was first performed by Dr Barnard in 1967, the procedure has proven to be the most effective and final treatment for end-stage heart failure. 1 However, the prognosis of heart transplant patients remains poor. Immune rejection remains to be the most significant challenge for heart transplant recipients despite the breakthrough use of immunosuppressive agents.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory effects of mesenchymal stem cells for the treatment of cardiac allograft rejection

Liang

Huang

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Heart transplantation continues to be the gold standard clinical intervention to treat patients with end-stage heart failure. However, there are major complications associated with this surgical procedure that reduce the survival prognosis of heart transplant patients, including allograft rejection, malignancies, infections, and other complications that arise from the use of broad-spectrum immunosuppression drugs. Recent studies have demonstrated the use of mesenchymal stem cells (MSCs) against allotransplantation rejection in both in vitro and in vivo settings due to their immunomodulatory properties. Therefore, utilization of MSCs provides new and exciting strategies to improve heart transplantation and potentially reduce the use of broad-spectrum immunosuppression drugs while alleviating allograft rejection. In this review, we will discuss the current research on the mechanisms of cardiac allograft rejection, the physiological and immunological characteristics of MSCs, the effects of MSCs on the immune system, and immunomodulation of heart transplantation by MSCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunomodulatory effects of mesenchymal stem cells for the treatment of cardiac allograft rejection

Liang

Huang

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Das galt auch noch für die in der Öffentlichkeit als spektakulär wahrgenommene erste Herztransplantation (Heart Exchange, HTX) im Jahre 1967 durch Christiaan Barnard. Die transplantierte Person überlebte die Operation nur wenige Tage 2 3 . Erst in den 1970er-Jahren, als mit dem Wirkstoff Ciclosporin das erste effektive immunsupprimierende Medikament entwickelt wurde, etablierte sich nach und nach die Transplantation verschiedenster Organe als fester Bestandteil des medizinischen Arsenals 1 4 .…”

unclassified

Der lange Weg in ein Leben mit einem neuen Herz

Mannebach¹,

Rakowski²,

Brakhage³

et al. 2023

intensiv

View full text Add to dashboard Cite

show abstract

“…To honour such a person does not remove from the tremendous achievement of Prof. Barnard and his surgical team, whose first 2 patients survived longer than those of his US counterparts at the time. [4] However, the failure to even mention Mr Naki seems an ongoing denial of the contributions of black South Africans to the advancement of science. This is a particularly inspiring story of what can be achieved even by the most disadvantaged when people work together regardless of racial background.…”

mentioning

confidence: 99%